The Mounjaro Dosing Chart: What Each Step in the Titration Schedule Actually Means

The decision at the start: why 2.5 mg exists and what changes at each rung

Most people who look up a tirzepatide dosing chart are trying to answer one of two questions: what comes next, or whether they are at the right dose already. If you want to see exactly where each strength sits in sequence, the Mounjaro chart lays out the full UK schedule from 2.5 mg through to 15 mg, with each step separated by roughly four weeks. That first pen at 2.5 mg is not doing much therapeutically. Its purpose is adjustment: slowing gastric emptying and altering appetite signals enough for your system to adapt before a meaningful dose is introduced. Nausea, loose stools and fatigue are commonest during transitions, not during steady periods, which is why the four-week gap between increases matters.

From 5 mg onward, each increase asks a practical question: is the current dose being tolerated, and is weight responding? Your prescriber reviews both before moving you up. The Mounjaro dosing guide covers how that clinical judgment works in practice. Plenty of people find a comfortable and effective position below the 15 mg ceiling, the chart is a ceiling, not a target.

The NHS tirzepatide medicine page summarises the licensed strength range and what to do if a dose is missed, and the SmPC on the eMC gives the full prescribing detail for clinicians. Both are worth bookmarking.

What the chart cannot tell you: individual variation and the prescriber's role

A question our prescribers hear most weeks is some version of: "The chart says 5 mg after four weeks, why hasn't mine been increased?" The answer is that the chart describes the licensed framework, not an automatic conveyor belt. Titration can slow down for good reasons: ongoing nausea at the current dose, a period of illness, a recent surgical procedure, or simply a prescriber's preference to consolidate before moving up. It can also pause entirely, some people stay at 7.5 mg or 10 mg long-term because that dose is doing the job without side effects, and adding more would only add risk.

This is especially relevant for anyone researching off-label microdosing approaches: these sit completely outside the licensed schedule and are not something a regulated UK prescriber can offer. The licensed steps exist for a reason, built from the clinical trial programme that tested safety and tolerability at each specific strength.

If you are transferring from another provider and want to understand where your current dose sits in the schedule, our tirzepatide overview explains what clinical evidence supports at each level.

How dose decisions connect to results, and what the trial data show

SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity, found average body-weight reductions of around 20–21% at the 15 mg dose. Lower maintenance doses produced meaningful but smaller average reductions. The point of the titration schedule is to reach the highest dose you tolerate well, not necessarily the highest dose that exists. Participants who stayed at 10 mg or 12.5 mg still achieved clinically significant weight loss; the chart is graduated precisely because a plateau at a mid-range dose is a valid endpoint, not a failure.

Head-to-head evidence from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. That comparison is relevant when choosing between medicines, but within the tirzepatide schedule itself the more useful comparison is between where you are and where you started.

For anyone weighing up the cost of moving through the full schedule, the context around Mounjaro's UK pricing is worth reading, Eli Lilly revised list prices from September 2025, and the private market range now varies considerably by dose and provider.

When to talk to your prescriber rather than the chart

The dosing chart is a reference, not a self-management tool. Several situations call for a conversation with your prescriber rather than a personal decision based on the schedule: if side effects have not eased within two weeks of a new dose; if you are planning surgery and need to know whether to pause treatment; if you are using oral contraceptives (for tirzepatide specifically, NHS guidance recommends adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be affected).

The tirzepatide dosing chart in a peptide context page covers how researchers use the compound differently from the licensed medicine, that distinction matters for anyone who has seen unlicensed sources online. Legitimate UK weight-loss treatment follows the SmPC schedule, dispensed through a GPhC-registered pharmacy.

If you'd like a prescriber to review where you sit in the schedule, or to start treatment for the first time, check your eligibility with our free consultation. A real clinician reads every submission the same day.